|
J Biol Chem, Vol. 275, Issue 19, 14017-14024, May 12, 2000
Defining the Carbohydrate Specificities of Aplysia
Gonad Lectin Exhibiting a Peculiar D-Galacturonic Acid
Affinity*
Albert M.
Wu §,
Shuh-Chyung
Song ,
Yuen-Yuen
Chen , and
Nechama
Gilboa-Garber¶
From the Glyco-Immunochemistry Research Laboratory,
Institute of Molecular and Cellular Biology, School of Medicine,
Chang-Gung University, Kwei-san 33332, Taiwan and the ¶ Faculty
of Life Sciences, Bar-Ilan University, Ramat Gan, 52900, Israel
 |
ABSTRACT |
Aplysia gonad lectin (AGL), which has
been shown to stimulate mitogenesis in human peripheral lymphocytes, to
suppress tumor cells, and to induce neurite outgrowth and improve cell
viability in cultured Aplysia neurons, exhibits a peculiar
galacturonic acid/galactose specificity. The carbohydrate binding site
of this lectin was characterized by enzyme-linked lectino-sorbent assay and by inhibition of AGL-glycan interactions. Examination of the lectin
binding with 34 glycans revealed that it reacted strongly with the
following glycoforms: most human blood group precursor (equivalent)
glycoproteins (gps), two Gal 1 4Gal-containing gps, and two
D-galacturonic acid (GalUA)-containing polysaccharides (pectins from apple and citrus fruits), but poorly with most human blood group A and H active and sialylated gps. Among the GalUA and
mammalian saccharides tested for inhibition of AGL-glycan binding,
GalUA mono- to trisaccharides were the most potent ones. They were
8.5 × 104 times more active than Gal and about
1.5 × 103 more active than the human blood group
Pk active disaccharide (E, Gal 1 4Gal). This
disaccharide was 6, 28, and 120 times more efficient than
Gal 1 3GlcNAc(I), Gal 1 3GalNAc(T), and Gal 1 4GlcNAc
(II), respectively, and 35 and 80 times more active than melibiose
(Gal 1 6Glc) and human blood group B active disaccharide
(Gal 1 3Gal), respectively, showing that the decreasing order of
the lectin affinity toward -anomers of Gal is 1 4 > 1 6 > 1 3. From the data provided, the carbohydrate
specificity of AGL can be defined as GalUA 1 4 trisaccharides to
mono GalUA > branched or cluster forms of E, I, and II
monomeric E, I, and II, whereas GalNAc is inactive.
 |
INTRODUCTION |
The reproductive organs of various molluscs are rich in lectin
activity (1, 2). Extracts of gonads and fertilized eggs of
Aplysia contain a D-galacturonic acid and
D-galactose-binding lectin (1, 2). This lectin
(Aplysia gonad lectin,
AGL)1 reacts with marine
microorganisms (3) and strongly agglutinates human papain-treated
erythrocytes regardless of ABO blood groups (2). It was purified by
heating to 70 °C, precipitated with ammonium sulfate, and affinity
chromatographed on Sepharose 4B (2). The purified lectin is a
glycoprotein of molecular mass of about 65 kDa, composed of two
identical subunits. It was shown to induce mitogenic stimulation and
interleukin-2 formation in human lymphocytes (4), to suppress
tumorigenicity of Lewis lung carcinoma cells (5), to modulate neurite
outgrowth in cultured Aplysia neurons, and to increase
neurite viability in vitro (6). AGL was also shown to be
useful for ultrastructural characterization of galacturonic acid in
plants and fungi (7) and for differentiation between I and i type human
erythrocytes (8). Moreover, it was recently found to be useful for
typing of halopilic Archaea and for the study of their S-layer
structure (9). Although AGL has been shown to be specific for GalUA and Gal, its detailed carbohydrate specificity has not been established. It
is important to elucidate the detailed carbohydrate specificity of this
lectin, because it may function as a signaling adhesion molecule and
has potential as a tool in experimental glycobiology, biochemistry, and
immunochemistry (4-9). In the present study, we defined the glycan
affinity of this lectin by both enzyme-linked biotin/avidin-mediated
microtiter plate lectin assay (ELLSA) and also by examination of the
inhibition of AGL-glycan interaction (10, 11). The great advantage of
this method is that the amount of lectin and glycoform required is
about 1/10 to 1/1000 of that required for the quantitative precipitin
assay (12, 13). The results show that the carbohydrate affinity
hierarchy of this lectin can be regarded as: tri-GalUA 1 4 to
mono-GalUA > branched and/or clusters of
E(Gal 1 4Gal), I(Gal 1 3GlcNAc), and/or
II(Gal 1 4 GlcNAc) monomeric E and
I > II, although GalNAc is inactive.
 |
EXPERIMENTAL PROCEDURES |
Lectin--
The AGL was purified from extracts of the gonads of
Aplysia depilans as described previously (2).
Biotinylation of the Lectin--
For AGL biotinylation by
biotinamidocaproate-N-hydroxy-succinimide ester (biotin
ester, purchased from Sigma), the purified lectin preparation (200 µg/250 µl of phosphate-buffered saline) was mixed with 400 µl of
the biotin ester solution (100 µg of biotin ester/200 µg of lectin)
and left for 30 min at room temperature. The biotinylated lectin was
dialyzed for 2-3 h against distilled H2O and overnight
against TBS. After dialysis, the sample volume was adjusted to 1 ml
with TBS, and 20 µl of 5% sodium azide was added (200 µg/ml AGL in
0.1% NaN3) (10-11).
Glycoproteins and Polysaccharides--
The blood group
substances were purified from human ovarian cyst fluid by the
procedures as described previously (14-19). Regardless of their A, B,
H, Lea, or Leb activity, the purified
water-soluble blood group substances have a similar overall structure.
They are polydispersed macromolecules (Mr
2.0 × 105 to 1.0 × 106) of similar
composition (75-85% carbohydrates, 15-20% protein). They bear
multiple heterosaccharide branches attached by glycosidic linkages at
their internal reducing ends to serine or threonine of the polypeptide
backbone (14-22).
The P-1 fractions of cyst glycoproteins represent the nondialyzable
portion of the blood group substances after mild hydrolysis at pH
1.5-2.0, 100 °C for 2 h, which removed most of the
L-fucopyranosyl end groups, as well as some blood group A
and B active oligosaccharide side-chains (14, 23, 24). The 1st
Smith-degraded products of blood group A active substances (MSS 10%
2X, see Table I), in which almost all of the sugar groups at the
nonreducing ends were removed, were prepared as described earlier (18,
20). Both P-1 fractions and 1st Smith degradation products, prepared from human ovarian cyst glycoprotein, are defined as precursor equivalent glycoproteins (Structure I,
25-28).

View larger version (10K):
[in this window]
[in a new window]
|
Structure I.
Proposed carbohydrate side chains of
blood group active glycoproteins prepared from human ovarian cyst
fluid. The blood group substance was purified from human ovarian
cyst fluid by digestion with pepsin and precipitation with ethanol; the
dried ethanol precipitates were extracted with 90% phenol, the
insoluble fraction being given after the name of the blood group
substance (e.g. Cyst Beach phenol insoluble). The supernatant was
fractionally precipitated by the addition of 50% ethanol in 95%
phenol to the indicated concentrations. The designation 10 or 20%(ppt)
denotes a fraction precipitated from phenol at an ethanol concentration
of 10 or 20%; 2X signifies that a second phenol extraction from
ethanol precipitation was carried (e.g. Cyst OG 20% 2×). The
4-branched structure (I IV) shown above represents the internal
portion of the carbohydrate moiety of blood group substances to which
the residues responsible for A, B, H, Lea, and
Leb activities are attached. This structure represents
precursor blood group active glycoproteins (25) and the precursor
equivalent gp can be prepared by Smith degradation of cyst A, B, and H
active glycoproteins (4, 19, 20, 22, 25) or mild acid hydrolysis (P-1
gp) (4, 12, 23, 24). Numbers in parentheses indicate the site of
attachment for the human blood group A, B, H, Lea, and
Leb determinants. These determinants as well as the
structural units at the nonreducing end are the sources of lectin
A/Ah, B, I, II,
T, and Tn determinants. A megalo-saccharide of 24 sugars has not been isolated. However, most of the carbohydrate chains
isolated are parts of this structure. For this structure, various human
blood group determinants are attached and illustrated in Table I.
|
|
The human blood group P1-active substance, purified from
sheep hydatid cyst glycoprotein (29, 30), was kindly provided by Dr.
W. M. Watkins (University of London, Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK). The mucus glycoprotein (native bird nest glycoprotein), the so-called nest-cementing substance
(Structure II), from the salivary gland
of Chinese swiftlets (genus Collocalia), was extracted with
distilled H2O at 60 °C for 20 min from the commercial
bird nest substance (Kim Hing Co., Singapore) (31, 32).
The mucus glycoproteins, the so-called
nest-cementing substances, from the salivary gland of Chinese swiftlets
(genus Collocalia) are mainly constituted of sialic
acid-rich O-glycosylproteins (31, 32). The most
complex representatives of the monosialyl fraction from
Collocalia mucin are shown. The other compounds
identified are partial structures thereof.
Structure II.
|
|
The Pneumococcus type XIV polysaccharide was prepared as
described previously (33, 34). Fetuin (Life Technologies, Inc.), which
is the major glycoprotein in fetal calf serum (35), has a molecular
mass of 48,400 with the following composition: 78% amino acids, 8.7%
sialic acid, 6.3% hexosamines, and 8.3% neutral sugars (36). It bears
six oligosaccharide side chains/molecule, three of them (of two types)
are O-glycosyl-linked to Ser or Thr residues of the protein
core, and the other three are N-glycosyl-linked to
asparagine (37-39).
The rat sublingual glycoprotein (RSL) was prepared by the method of
Moschera and Pigman (40). Its molecular mass is 2.2 × 106 and it contains 81% carbohydrates (40). The
carbohydrate side-chains (Structure III)
are O-glycosyl-linked to Ser or Thr residues of the protein
core. The established structure has 9, 10, 12, 13, and 15 sugar
residues with NeuNAc 2,6 linked to Gal, GalNAc 1 Ser/Thr (Tn), and GlcNAc groups at the nonreducing ends, as well as
a repeating unit, Gal 1 4GlcNAc 1 , in the carbohydrate core structure (Structure III) (41). It was found that its carbohydrate chains also contain the Tn active determinant (42).
Established structure of the
carbohydrate moiety of asialo rat sublingual glycoprotein contains the
following chains of three different lengths. Most of the
carbohydrate chains are parts of this structure (40, 41). Furthermore,
variations in this ratio and in chain lengths are expected to occur in
different mucin preparations (42).
Structure III.
|
|
Porcine salivary mucin (PSM), bovine submandibular glycoprotein-major,
and armadillo salivary glycoprotein were purified according to the
method of Tettamanti and Pigman (43) with some modifications (44-47).
Sialic acids were removed from sialylated glycoproteins by mild acid
hydrolysis with 0.01 N HCl at 80 °C for 90 min and dialyzed against
distilled water for 2 days to remove small fragments (47).
Hog gastric mucin 4 (48) and its mild acid degraded products (Hog
gastric mucin 9, Hog gastric mucin 14, and Hog gastric mucin 21) were
prepared according to the method previously described (49). Human
1-acid glycoprotein (50, 51) and pectins from apple and
citrus fruits were purchased from Sigma.
Monosaccharides and Oligosaccharides Used for Inhibition
Assay--
GalUA, GalUA 1 4GalUA, GalUA 1 4GalUA 1 4GalUA,
and all other sugar ligands were purchased from Sigma.
The Microtiter Plate Lectin-Enzyme Binding Assay
(ELLSA)--
ELLSA was performed according to the procedures of Duk
et al. (10) or as described previously (12, 13). The volume
of each reagent applied to the plate was 50 µl/well, and all
incubations, except for coating, were performed at 20 °C. The
reagents, if not otherwise indicated, were diluted with TBS containing
0.05% Tween 20. The TBS buffer or 0.15 M NaCl containing
0.05% Tween 20 was used for washing the plates between incubations.
For inhibition studies, the serially diluted inhibitor samples were
mixed with an equal volume of lectin solution containing a fixed amount
of lectin. The control lectin sample was diluted 2-fold with TBS
containing 0.05% Tween 20. After 30 min at 20 °C, the samples were
tested in the binding assay, as described above. The inhibitory
activity was estimated from the inhibition curve and expressed as the
amount of inhibitor (nmol/well) giving 50% inhibition of the control
lectin binding.
All experiments were done in duplicate or triplicate, and the data
presented are mean values of the results. The standard deviation did
not exceed 10% and in most experiments was less than 5% of the mean
value. The control wells, where either coating or addition of
biotinylated lectin was omitted, gave low absorbance values (below 0.1, read against the well filled with buffer) and were used as blank. It
has been shown that blocking the wells before lectin addition was not
necessary when Tween 20 was used in TBS.
 |
RESULTS AND DISCUSSION |
Lectin-Glycan Interactions--
The avidity of AGL for gps and
polysaccharides, as studied by a microtiter plate ELLSA, is summarized
in Table II according to the interaction
profiles shown in Fig. I. AGL reacted most strongly with five human
blood group precursor-equivalent gps related to Structure I (Cyst OG,
Cyst Mcdon P-1, and Cyst MSS 1st Smith in Fig.
1c; Cyst Beach P-1 in Fig.
1d; and Cyst Tighe P-1 in Fig. 1e), two
Gal 1 4Gal-containing gps (asialo bird nest gp and sheep hydatid
cyst gp, Fig. 1b), and two GalUA-containing fruit
polysaccharides (pectin A from apple and pectin C from citrus, Fig.
1a). AGL also bound well asialo rat sublingual gp (Fig.
1h), blood group B active gp from human ovarian cyst fluid
(Cyst Tij, Fig. 1d), and asialo PSM (Fig. 1i).
Because the percentage of glycans adsorbed onto the microtiter plate
had not been established, the amount of glycans required to reach
maximum interaction could not be evaluated. However, their binding
reactivities were confirmed by the inhibition of AGL-glycan interaction
with various glycans, as described under "Inhibition of AGL-Glycoform
Interaction by Various Glycans" (Fig. 2
and Table III).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
Binding of AGL to microtiter plates coated
with serially diluted human blood group A, B, O, P1,
Leb, and Ii active glycoproteins, sialo and asialo
glycoproteins and polysaccharides. The lectin was used at a
constant amount of 5 ng/well. Total volume 50 µl.
A405 was recorded after 2 h of
incubation.
|
|

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Inhibition of AGL binding to Cyst Beach
P-1-coated enzyme-linked immunosorbent assay plates with various
glycoproteins and Tn-containing glycopeptides. The quantity of
Cyst Beach P-1 in the coating solution was 10 ng/well. The quantity of
lectin used for inhibition assay was 5 ng/well. Total volume, 50 µl.
A405 was recorded after a 2-h incubation. When
277.8 ng of glycoprotein were used to inhibit AGL-Beach P-1
glycoprotein binding, the concentration required to induce 50%
inhibition was determined. In this assay, Hog gastric mucin 4; Hog
gastric mucin 9; Cyst MSS 10% 2x; Cyst Mcdon; PSM; Cyst JS phenol
insoluble; Cyst Tighe phenol insoluble; RSL; fetuin; asialo fetuin;
bovine submandibular gp-major; asialo bovine submandibular gp-major;
OSM; asialo OSM (curves 22 to 35) did not reach 50% inhibition.
|
|
Except the bird nest gp [Fig. 1b], the blood group A, B, H or
Leb substances and mammalian salivary gps containing
Gal 1 4GlcNAc and Gal 1 3GalNAc masked by sialic acids were
either weakly active or inactive (Fig. 1 and Table
II). These included cyst MSS 10% 2x(A1) (Fig. 1c), cyst Mcdon (A1)
(Fig. 1c), cyst JS phenol insoluble(H) (Fig. 1e),
cyst Tighe phenol insoluble (H+Leb) (Fig. 1e);
hog gastric mucin 4 (A+H) (Fig. 1f), rat sublingual gp (Fig.
1h), and PSM (Fig. 1i). Neither native salivary
gps nor asialo products containing exposed Tn determinants
only (Fig. 1i) reacted with AGL.
View this table:
[in this window]
[in a new window]
|
Table II
Binding of AGL lectin to human blood group A, B, H, P1 and
Leb active glycoproteins (gps), sialo- and asialo glycoproteins
by ELLSA
5 ng of biotinylated lectin was added to glycoprotein concentrations
ranging from 0.12 to 10 µg.
|
|
Inhibition of AGL-Glycoform Interaction by Various
Glycans--
The abilities of various glycans to inhibit the binding
of AGL with Cyst Beach P-1 glycoprotein by ELLSA were analyzed and are
shown in Fig. 2 and Table III. Among the
glycans tested for inhibition of that interaction, six human blood
group precusor equivalent gps (curves 1, 5, 6, 9, 10, and 11 in Fig. 2
and Table III); two Gal 1 4Gal containing glycoproteins (sheep
hydatid cyst gp and asialo bird nest, curves 3 and 4 of Fig. 2 and
Table III), and two GalUA-containing polysaccharides (pectin-A and
pectin-C, curves 7 and 8 of Fig. 2 and Table III) were the best
inhibitors, requiring less than 12 ng to inhibit 50% of the
interaction. They were much more active than monomeric Gal 1 4Gal
and Gal but much weaker than GalUA (Fig. 2 and Table III). The
precursor equivalent and asialo glycoproteins were much more active
than their further glycosylated, native or sialylated compounds (curve
4 versus curve 19, curves 5 and 6 versus
corresponding native compounds in Fig. 2 and Table III, etc.). The
decreasing order of the reactivity of these glycoforms is Cyst OG 10%
2x PPT (one of the human blood group precursor gps, Structure I, curve
1 in Fig. 2) and sheep hydatid cyst gp (blood group P1
active gp) (curve 3 in Fig. 2) > asialo bird nest gp (curve 4),
five human blood group precursor gps (curves 5, 6, 9, 10, and 11) and
two GalUA-containing gps; pectin-A and pectin-C (curves 7 and 8) > a blood group B active gp (curve 12); mild acid-hydrolyzed hog
gastric mucin 14 (II), hog mucin 21 (II), and
asialo rat sublingual gp (II, structure III) blood
group A and H active glycoproteins and sialylated glycoproteins (Figs.
2 and 4). With several exceptions, the inhibitory reactivities of
glycoforms toward AGL agree, in general, with the maximum absorbance
values recorded in the binding assay (Fig. 1 and Table II).
View this table:
[in this window]
[in a new window]
|
Table III
Amount of various glycoproteins giving 50% inhibition of AGL (5 ng/50
µl)-Cyst Beach P 1 gp (10 ng/50 µl) binding
The inhibitory activity was estimated from the respective inhibition
curve in Fig. 2 and is expressed as the amount of inhibitor
(nanogram) giving 50% inhibition. Total volume 50 µl.
GalUA: 4 × 103 nanogram is equal to 2 ×10 5
nmol, Gal 1 4Gal: 850 nanograms is equal to 2.5 nmol, Gal: 7 × 103 nanograms is equal to 3.9 × 10 2 nmol.
Glycans that did not reach 50% inhibition are described in the legend
to Fig. 2.
|
|
The weak or negative reactivity of AGL with A and H active gps and most
sialylated gps (Cyst Mcdon and Cyst MSS (Fig. 1c), Cyst
Beach phenol insoluble (Fig. 1d), Cyst Tighe phenol
insoluble (Fig. 1e)), human 1-acid gp (Fig.
1g), RSL (Fig. lh), and PSM (Fig. 1i))
could be ascribed to the masking effects of LFuc 1 , GalNAc 1 , and sialic acid at the terminal Gal 1 and/or poor adsorbance of these glycoforms onto a microwell plate.
Mild acid hydrolysis (pH 1.5, 100 °C for 2 h), which removes
the terminal L-Fuc 1 linked and some blood group A and
B active oligosaccharide side chains (14-17), and Smith degradation,
which removes almost all nonreducing terminal sugars, should
significantly increase their interactions with this lectin (Tables II
and III and Figs. 1 and 2) (18). The Gal 1 determinant of human
blood group precursor or precusor equivalent gp (Structure I) is
similar to Bombay type erythrocytes (Oh) that are more
strongly agglutinated by this lectin than the O(H) blood type (8).
Inhibition of Lectin-Glycan Interaction by Mono- and
Oligosaccharides--
The ability of various sugars to inhibit the
binding of AGL to cyst Beach P-1 gp (human blood group precursor
equivalent gp purified from human ovarian cyst fluid) is shown in Fig.
3, and the amounts of ligand required for
50% inhibition of the lectin-glycan interaction are listed in Table
IV. Among the oligo- and monosaccharides tested, di > tri-GalUA 1 4 to mono-GalUA were the most
active, up to 8.5 × 104 times more active than Gal,
indicating that COOH at carbon-6 is the most important factor for
binding. GalUA was about 1.5 × 103 times more
active than human blood group Pk active disaccharides
(E, Gal 1 4Gal), which was 6, 28, and 120 times more
active than Gal 1 3GlcNAc(I),
Gal 1 3GalNAc(T), and Gal 1 4GlcNAc
(II), respectively. These results, show that each
lectin has its own binding characteristics (26-28) and that the
carbohydrate specificity of AGL can be defined as GalUA 1 4 di > trisaccharides to mono GalUA > branched or cluster forms of
E, I, and II monomeric
E(Gal 1 4Gal) > I(Gal 1 3GlcNAc) > T(Gal 1 3GalNAc) > B(Gal 1 3Gal) > II(Gal 1 4GlcNAc),
and L(lactose).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibition of AGL binding to human cyst Beach
P-1 (human blood group precusor equivalent) gp-coated enzyme-linked
immunosorbent assay plates by various saccharides. The amount of
glycoproteins in the coating solution was 10 ng/well. The lectin (10 ng/well) was preincubated with an equal volume of serially diluted
inhibitor. The final lectin content was 5 ng/well. Total volume, 50 µl. A405 was recorded after 2 h of
incubation. The following sugar inhibitors were tested from 80 to 556 nmol and found to be inactive-GalNAc, L-Ara,
GlcNAc, Glc, methyl- -Glc, methyl- -Glc,
p-NO2-phenyl- -GalNAc, GlcNAc 1 4GlcNAc, and
GalNAc 1 3Gal-O-methyl.
|
|
View this table:
[in this window]
[in a new window]
|
Table IV
Amount of various saccharides giving 50% inhibition of AGL binding (5 ng/50 µl) to Cyst Beach P-1 gp (10 ng/50 µl)
The inhibitory activity was estimated from the inhibition curve in Fig.
3 and is expressed as the amount of inhibitor giving 50% inhibition.
Total volume 50 µl.
|
|
Gal 1 4Man was about 2.5 times less active than
Gal 1 3GlcNAc (I), but 6.7 and 8 times more active
than Gal 1 4Glc(L) and Gal 1 4GlcNAc
(II), respectively. These results show that the
configuration at C-2 in the subterminal hexopyranose is also important
for the binding and that substitution with NHCOCH3 at C-2
reduces the inhibitory power. Melibiose and raffinose
(Gal 1 6Gal 1 2DFructo-furanoside) were almost
equally active and 4.0 times more active than stachyose (Gal 1 6Gal 1 6Glc 1 2DFructofuranoside),
suggesting that the combining size for 1 6 oligosaccharides is
probably most accessible with less than a trisaccharide structure.
Among -anomers of Gal tested, Gal 1 4Gal was 35 and 80 times
more active than melibiose (Gal 1 6Glc) (curve 10 in Fig.
3a and Table IV) and Gal 1 3Gal (curve 21 in Fig.
3b and Table IV), respectively. Hence, the decreasing order
of preference of the lectin for -anomers of Gal is: 1 4 > 1 6 > 1 3.
Of the monosaccharide derivatives studied, phenyl Gal (Fig.
3a, curve 9) was the best inhibitor 2 × 104 times less active than GalUA (Fig. 3b, curve
3), but 1.8 times more active than Gal and 1.2 times more than
p-NO2-phenyl Gal and
p-NO2-phenyl Gal. As shown in Table IV, the
phenyl -derivative of Gal was about 2 times better than the
methyl- -derivative (Fig. 3, curves 13 versus 20), whereas
no significant difference was observed between the methyl- and
p-NO2phenyl derivatives of -Gal (Fig.
3a, curves 12 and 14).
GalNAc, which was tested up to a concentration exceeding that of Gal
inducing 50% inhibition by 2.4-fold (Fig. 3 and Table IV), was
inactive indicating that the N-acetamido group at C-2 of the
Gal pyranose ring strongly interferes with its interaction with AGL.
D-Fuc and L-Ara showed no inhibition up to
three times the amount of Gal giving 50% inhibition, suggesting that
the OH group at C-6 or the CH2OH at C-6 of Gal is essential
for lectin binding. GlcNAc, Glc, methyl- -Glc, and methyl- -Glc
were tested at concentrations from 380 to 463 nmol, but no inhibition
of lectin binding was observed.
From these assays, we conclude that the major contributions of this
study are: 1) establishment of the binding relationship between AGL and
mammalian carbohydrate structural units; 2) illustration of the high
specificity of AGL for GalUA-related glycotopes, which is rare and is
an important consideration in animal lectins; 3) demonstration that the
COO group rather than OH at carbon-6
dramatically enhances binding reactivity; and 4) presentation that the
presence of carboxylated ( COOH) or hydroxylated ( OH) carbon-6 and
the configuration of Gal at carbon-4 are essential for binding (Gal
versus Glc). This information should be useful for
elucidating the mechanism of adhesion in the life process of
Aplysia and other aspects of glycobiology.
 |
FOOTNOTES |
*
This work was supported by Grant 676 from the Chang-Gung
Medical Research Project, Kwei-san, Tao-yuan, Taiwan and Grants
86-2316-B182-001-BC and 84-2811-B182-001R from the National Science
Council, Taipei, Taiwan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Glyco-Immunochemistry
Research Laboratory, Inst. of Molecular and Cellular Biology, Chang-Gung Medical College, Kwei-san 333, Taiwan. Tel.: 886-3-328-6966; Fax: 886-3-328-6456 (laboratory) or 886-3-328-3031 (college); E-mail:
amwu@mail.cgu.edu.tw.
 |
ABBREVIATIONS |
The abbreviations used are:
AGL, Aplysia gonad lectin;
GalUA, D-galacturonic
acid;
Gal, D-galactopyranose;
ELLSA, enzyme-linked
lectino-sorbent assay;
TBS, Tris-buffered saline;
Glc, D-glucopyranose;
GlcNAc, 2-acetamido-2-deoxy-D-glucopyranose;
PSM, porcine salivary
gp major;
LFuc or Fuc, L-fucopyranose;
GalNAc, 2-acetamido-2-deoxy-D-galactopyranose;
gp, glycoprotein;
RSL, rat sublingual gp major;
OSM, ovine submandibular gp major;
BSM, bovine salivary gp major;
NeuNAc, N-acetylreuraminic acid.
Lectin determinants that are used to classify applied lectins are
expressed in bold: A (GalNAc 1 3Gal), Ah
(GalNAc 1 3[LFuc 1 2]Gal), B
(Gal 1 3Gal), T (Gal 1 3GalNAc),
I/II (Gal 1 3/4GlcNAc), F (GalNAc 1 3GalNAc), L (Gal 1 4Glc), Tn
(GalNAc 1 Ser/Thr), E (Gal 1 4Gal, the human blood
group Pk active disaccharide, which is also part of
P1 determinant, but this disaccharide is not the key
sequence for its reactivity) (26-28).
 |
REFERENCES |
| 1.
|
Gilboa-Garber, N.,
Mizrahi, L.,
and Susswein, A. J.
(1984)
Mar. Biol. Lett.
5,
105-114
|
| 2.
|
Gilboa-Garber, N.,
Susswein, A. J.,
Mizrahi, L.,
and Avichezer, D.
(1985)
FEBS Lett.
181,
267-270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Zipris, D.,
Gilboa-Garber, N.,
and Susswein, A. J.
(1986)
Microbios.
46,
193-198[Medline]
[Order article via Infotrieve]
|
| 4.
|
Zipris, D.,
and Gilboa-Garber, N.
(1987)
Develop. Comp. Immunol.
11,
501-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Avichezer, D.,
Leibovici, J.,
Gilboa-Garber, N.,
and Michowitz, M.
(1987)
in
Lectures and Symposia 14th International Cancer Cong. Budapest, 1986
(Lapis, K.
, and Ackhardt, S., eds), Vol. 2
, pp. 79-86, Karger, Basel, New York
|
| 6.
|
Wilson, M. P.,
Carrow, G. M.,
and Levitan, I. B.
(1992)
J. Neurobiology
23,
739-750[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Benhamou, N.,
Gilboa-Garber, N.,
Trudel, J.,
and Asselin, A.
(1988)
J. Histochem. Cytochem.
36,
1403-1412[Abstract]
|
| 8.
|
Sudakevitz, D.,
Levene, C.,
and Gilboa-Garber, N.
(1996)
in
Lectins: Biology, Biochemistry, Clinical Biochemistry
(Van Driessche, E.
, Rougé, P.
, Beeckmans, S.
, and Bøg-Hansen, T. C., eds), Vol. 11
, pp. 207-211, Textop Hellerup, Denmark
|
| 9.
|
Gilboa-Garber, N.,
Mymon, H.,
and Oren, A.
(1998)
FEMS Microbiol. Lett.
163,
91-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Duk, M.,
Lisowska, E.,
Wu, J. H.,
and Wu, A. M.
(1994)
Anal. Biochem.
221,
266-272[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Lisowska, E.,
Duk, M.,
and Wu, A. M.
(1996)
BioMethods
7,
115-129
|
| 12.
|
Wu, A. M.,
Song, S. C.,
Chang, S. C.,
Wu, J. H.,
Chang, K. S. S.,
and Kabat, E. A.
(1997)
Glycobiology
7,
1061-1066[Abstract/Free Full Text]
|
| 13.
|
Chen, C. P.,
Song, S. C.,
Gilboa-Garber, N.,
Chang, K. S. S.,
and Wu, A. M.
(1998)
Glycobiology
8,
7-16[Abstract/Free Full Text]
|
| 14.
|
Beiser, S. M.,
and Kabat, E. A.
(1952)
J. Immunol.
68,
19-40
|
| 15.
|
Kabat, E. A.
(1956)
Blood Group Substances. Their Chemistry and Immunochemistry
, pp. 135-139, Academic Press, New York
|
| 16.
|
Allen, P. Z.,
and Kabat, E. A.
(1959)
J. Immunol.
82,
340-357
|
| 17.
|
Vicari, G.,
and Kabat, E. A.
(1969)
J. Immunol.
102,
821-825[Abstract/Free Full Text]
|
| 18.
|
Lloyd, K. O.,
and Kabat, E. A.
(1968)
Proc. Natl. Acad. Sci. U. S. A.
61,
1470-1477[Free Full Text]
|
| 19.
|
Maisonrouge-McAuliffe, F.,
and Kabat, E. A.
(1976)
Arch. Biochem. Biophys.
175,
81-89[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Wu, A. M.,
Kabat, E. A.,
Pereira, M. E. A.,
Gruezo, F. G.,
and Liao, J.
(1982)
Arch. Biochem. Biophys.
215,
390-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Vicari, G.,
and Kabat, E. A.
(1970)
Biochemistry
9,
3414-3421[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Wu, A. M.,
Kabat, E. A.,
Nilsson, B.,
Zopf, D. A.,
Gruezo, F. G.,
and Liao, J.
(1984)
J. Biol. Chem.
259,
7178-7186[Abstract/Free Full Text]
|
| 23.
|
Kabat, E. A.,
Baer, H.,
Bezer, A. E.,
and Knaub, V.
(1948)
J. Exp. Med.
88,
43-57[Abstract]
|
| 24.
|
Leskowitz, S.,
and Kabat, E. A.
(1954)
J. Am. Chem. Soc.
76,
5060-5065[CrossRef]
|
| 25.
|
Wu, A. M.
(1988)
Adv. Exp. Med. Biol.
228,
351-394[Medline]
[Order article via Infotrieve]
|
| 26.
|
Wu, A. M.,
and Sugii, S.
(1991)
Carbohydr. Res.
213,
127-143[CrossRef]
|
| 27.
|
Wu, A. M.,
and Sugii, S.
(1988)
Adv. Exp. Med. Biol.
228,
205-263[Medline]
[Order article via Infotrieve]
|
| 28.
|
Wu, A. M.,
Song, S. C.,
Sugii, S.,
and Herp, A.
(1997)
Ind. J. Biochem. Biophys.
34,
61-71[Medline]
[Order article via Infotrieve]
|
| 29.
|
Cory, H. T.,
Yates, A. D.,
Donald, A. S.,
Watkin, W. M.,
and Morgan, W. T. J.
(1974)
Biochem. Biophys. Res. Commun.
61,
1289-1296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
| Morgan, W. T. J., and Watkins, W. M. (1964)
Proceedings of the 9th Congr. International Society for Blood
Transfusion, Mexico 1962, pp. 225-229
|
| 31.
|
Wieruszeski, J. M.,
Michalski, J. C.,
Montreuil, J.,
Strecker, G.,
Peter-Katalinic, J.,
Egge, H.,
van Halbeek, H.,
Mutsaers, J. H. G. M.,
and Vliegenthart, J. F. G.
(1987)
J. Biol. Chem.
262,
6650-6657[Abstract/Free Full Text]
|
| 32.
|
Wu, A. M.,
Song, S.-C.,
Hwang, P.-Y.,
Wu,
June, H.,
and Kabat, E. A.
(1995)
Biochem. Biophys. Res. Commun.
216,
814-820[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Lindberg, B.,
Lonngren, J.,
and Powell, D. A.
(1977)
Carbohydr. Res.
58,
177-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Howe, C.,
Schiffman, G.,
Bezer, A. E.,
and Kabat, E. A.
(1958)
J. Am. Chem. Soc.
80,
6656-6661[CrossRef]
|
| 35.
|
Spiro, R. G.,
and Bhoyroo, V. D.
(1974)
J. Biol. Chem.
249,
5704-5717[Abstract/Free Full Text]
|
| 36.
|
Graham, E. R. B.
(1972)
in
Glycoproteins
(Gottschalk, A., ed), 2nd Ed.
, pp. 722-723, Elsevier, Amsterdam
|
| 37.
|
Nilsson, B.,
Norden, N. E.,
and Svensson, S.
(1979)
J. Biol. Chem.
254,
4545-4553[Free Full Text]
|
| 38.
|
Townsend, R. R.,
Hardy, M. R.,
Wong, T. C.,
and Lee, Y. C.
(1986)
Biochemistry
25,
5716-5725[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Edge, A. S. B.,
and Spiro, R. G.
(1987)
J. Biol. Chem.
262,
16135-16141[Abstract/Free Full Text]
|
| 40.
|
Moschera, J.,
and Pigman, W.
(1975)
Carbohydr. Res.
40,
53-67[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Slomiany, A.,
and Slomiany, B. L.
(1978)
J. Biol. Chem.
253,
7301-7306[Abstract/Free Full Text]
|
| 42.
|
Wu, A. M.,
Herp, A.,
Song, S. C.,
Wu, J. H.,
and Chang, K. S. S.
(1995)
Life Sci.
57,
1841-1852[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Tettamanti, G.,
and Pigman, W.
(1968)
Arch. Biochem. Biophys.
124,
41-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Herp, A.,
Wu, A. M.,
and Moschera, J.
(1979)
Mol. Cell. Biochem.
23,
27-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Herp, A.,
Borelli, C.,
and Wu, A. M.
(1988)
Adv. Exp. Med. Biol.
228,
395-435[Medline]
[Order article via Infotrieve]
|
| 46.
|
Fournet, B.,
Montreuil, J.,
Strecker, G.,
Dorland, L.,
Haverkamp, J.,
Vliegenthart, J. F. G.,
Binette, J. P.,
and Schmid, K.
(1978)
Biochemistry
17,
5206-5214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Wu, A. M.,
and Pigman, W.
(1977)
Biochem. J.
161,
37-47[Medline]
[Order article via Infotrieve]
|
| 48.
|
Van Halbeek, H.,
Dorland, L.,
Vliegenthart, J. F. G.,
Kochetkov, N. K.,
Arbatsky, N. P.,
and Derevitskaya, V. A.
(1982)
Eur. J. Biochem.
127,
21-29[Medline]
[Order article via Infotrieve]
|
| 49.
|
Wu, A. M.,
Lin, S.-R.,
Chin, L.-K.,
Chow, L.-P.,
and Lin, J.-Y.
(1992)
J. Biol. Chem.
267,
19130-19139[Abstract/Free Full Text]
|
| 50.
|
Schmid, K.,
Binette, J. P.,
Dorland, L.,
Vliegenthart, J. F. G.,
Fournet, B.,
and Montreuil, J.
(1979)
Biochim. Biophys. Acta
581,
356-359[Medline]
[Order article via Infotrieve]
|
| 51.
|
Fournet, B.,
Montreuil, J.,
Strecker, G.,
Dorland, L.,
Haverkamp, J.,
Vliegenthart, J. F. G.,
Binette, J. P.,
and Schmid, K.
(1978)
Biochemistry
17,
5206-5214
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. M. Wu, T. Singh, J. H. Wu, M. Lensch, S. Andre, and H.-J. Gabius
Interaction profile of galectin-5 with free saccharides and mammalian glycoproteins: probing its fine specificity and the effect of naturally clustered ligand presentation
Glycobiology,
June 1, 2006;
16(6):
524 - 537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Singh, U. Chatterjee, J. H. Wu, B. P. Chatterjee, and A. M. Wu
Carbohydrate recognition factors of a T{alpha} (Gal{beta}1->3GalNAc{alpha}1->Ser/Thr) and Tn (GalNAc{alpha}1->Ser/Thr) specific lectin isolated from the seeds of Artocarpus lakoocha
Glycobiology,
January 1, 2005;
15(1):
67 - 78.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|